Cara Mathews Source Confirmed

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Assistant Professor

John Brown University

faculty

34 h-index 241 pubs 8,219 cited

Research Areas

Links

ORCID

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dr. Cara Mathews is an Assistant Professor at John Brown University whose research is centered on cancer genomics and diagnostics, with a particular interest in gynecologic malignancies and colorectal cancer. Her work spans the spectrum of cancer research, from investigating genetic factors that predispose individuals to colorectal cancer to exploring novel diagnostic and treatment strategies for endometrial, cervical, and ovarian cancers. Recent publications reflect her engagement with cutting-edge clinical trials, including studies evaluating the efficacy of pembrolizumab in advanced endometrial cancer and atezolizumab plus bevacizumab and chemotherapy for metastatic cervical cancer. Mathews also investigates maintenance therapies, such as olaparib for ovarian cancer, and the use of dostarlimab in treating endometrial cancer with mismatch repair deficiencies. Her research extends to optimizing treatment protocols, as shown by her contributions to trials comparing adjuvant chemotherapy following chemoradiotherapy versus chemoradiotherapy alone for locally advanced cervical cancer.

Metrics

h-index: 34
Publications: 241
Citations: 8,219

Selected Publications

Preliminary results from a first-in-human, phase I/II study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced solid tumors. (2025) DOI
Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) (2025) DOI
Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis (2025) DOI
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial (2025) DOI
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers (2025) DOI
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial (2024) DOI
Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial (2024) DOI
718MO Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial (2024) DOI
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. (2024) DOI
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study (2024) DOI
Normal Risk Ovarian Screening Study: 21-Year Update (2024) DOI
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial (2023) DOI
LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial (2023) DOI
Evolution of peripheral and tumor immune parameters as biomarkers of differential sequencing of immune checkpoint blockade and chemoradiotherapy in locally advanced cervical cancer: An NRG Oncology/GOG Study (006) (2023) DOI
Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm (2023) DOI